---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-120676"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:36:27.567104+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics appoints Christopher Martin to board; Cameron Turtle resigns

## Summary
- Cameron Turtle resigned as director on Dec 11, 2025; not due to disagreement with the company.
- Christopher Martin appointed as Class II director, Chair of Compensation Committee, and Audit Committee member.
- Martin previously Chief Commercial Officer at Verona Pharma, acquired by Merck for ~$10B in Oct 2025.
- He received an option to buy 35,000 shares vesting over 3 years; annual cash retainers: $40K (board), $12K (Comp Chair), $7.5K (Audit).
- Martin also serves on the board of Edgewise Therapeutics (EWTX).

## SEC filing metadata
- accession: 0001213900-25-120676
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390025120676/0001213900-25-120676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390025120676/ea0268925-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-120676
- JSON: https://secwatch.observer/filing/0001213900-25-120676.json
- Plain text: https://secwatch.observer/filing/0001213900-25-120676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.